Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 3;6(9):3755-3763.
doi: 10.3390/ma6093755.

Construction of a Novel Magnetic Targeting Anti-Tumor Drug Delivery System: Cytosine Arabinoside-Loaded Bacterial Magnetosome

Qiongjia Deng  1 , Yuangang Liu  2   3 , Shibin Wang  4   5 , Maobin Xie  6 , Shenjian Wu  4 , Aizheng Chen  7   8 , Wenguo Wu  9   10
Affiliations

Construction of a Novel Magnetic Targeting Anti-Tumor Drug Delivery System: Cytosine Arabinoside-Loaded Bacterial Magnetosome

Qiongjia Deng et al. Materials (Basel). .

Abstract

To ease the side effects triggered by cytosine arabinoside (Ara-C) for acute leukemia treatment, a novel magnetic targeting anti-tumor drug delivery system was constructed through bacterial magnetosomes (BMs) from Magnetospirillum magneticum AMB-1 combined with Ara-C by crosslinking of genipin (GP). The results showed that Ara-C could be bonded onto the membrane surface of BMs effectively through chemical crosslinking induced by dual hand reagents GP. The average diameters of BMs and Ara-C-coupled BMs (ABMs) were 42.0 ± 8.6 and 72.7 ± 6.0 nm respectively, and the zeta potentials (-38.1 ± 9.1) revealed that these systems were stable, confirming the stability of the system. The optimal encapsulation efficiency and drug loading were 89.05% ± 2.33% and 47.05% ± 0.64% respectively when crosslinking reaction lasted for 72 h. The system also presented long-term stability and release behaviors without initial burst release (Ara-C could be released 80% within three months). Our results indicate that BMs have great potential in biomedical and clinical fields as a novel anti-tumor drug carrier.

Keywords: cytosine arabinoside; drug release; genipin; magnetosome.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
TEM images of bacterial magnetosomes (BMs) and Ara-C-coupled BMs (ABMs): (a and b: BMs) and (c and d: ABMs); (b) BMs showed the narrow size distribution and uniform lipid membrane; (d) Black arrow pointed to thickened and blurred materials surrounding ABMs.
Figure 2
Figure 2
The FTIR spectra of Ara-C, ABMs and BMs.
Figure 3
Figure 3
Drug loading and encapsulation efficiency of ABMs prepared with different reaction time by genipin (GP).
Figure 4
Figure 4
Cumulative release of (a) free Ara-C and (b) ABMs.
See this image and copyright information in PMC

References

    1. Tallman M.S., Gilliland D.G., Rowe J.M. Drug therapy for acute myeloid leukemia. Blood. 2005;106:1154–1163. doi: 10.1182/blood-2005-01-0178. - DOI - PubMed
    1. Krogh-Madsen M., Bender B., Jensen M.K., Nielsen O.J., Friberg L.E., Honóre P.H. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemother. Pharmacol. 2012;69:1155–1163. doi: 10.1007/s00280-011-1800-z. - DOI - PubMed
    1. Elli M., Bozkurt A., Dagdemir A., Pinarli F.G., Acar S. Protective effect of vitamin A on ARA-C induced intestinal damage in mice. Tumori. 2009;95:87–90. - PubMed
    1. Keime-Guibert F., Napolitano M., Delattre J.Y. Neurological complications of radiotherapy and chemotherapy. J. Neurol. 1998;245:695–708. doi: 10.1007/s004150050271. - DOI - PubMed
    1. Kwong Y.L., Yeung D.Y.M., Chan J.C.W. Intrathecal chemotherapy for hematologic malignancies: drugs and toxicities. Ann. Hematol. 2009;88:193–201. doi: 10.1007/s00277-008-0645-y. - DOI - PubMed